Belén Garijo named Merck Serono CEO

Chutes and Ladders

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email | Twitter) and we will feature it here at the end of each week.

Belén Garijo named Merck Serono CEO

Merck KGaA has named former COO Belén Garijo its new president and CEO of the company's biopharmaceutical division, Merck Serono. Garijo will succeed Stefan Oschmann, who will remain a member of the executive board and the head of pharmaceuticals at Merck. FiercePharma story | Release

Merck Serono
Belén Garijo will become president and CEO.


Illumina
Richard Klausner will become senior vice president and chief medical officer.


Biotech

> Dr. Francesco Granata has been appointed to the board of directors at Circassia as nonexecutive chairman. Granata is executive in residence at Warburg Pincus and most recently served as executive vice president at Biogen Idec ($BIIB). Release

Stellar Biotechnologies has appointed Tessie Mary Che to its board of directors. Che is the cofounder of Optimer Pharmaceuticals ($OPTR) and is currently chair of the board of directors of Amaran Biotechnology. Release

InterMune ($ITMN) today announced that Andrew Powell has joined the company as executive vice president, general counsel and corporate secretary. Powell most recently served as executive vice president, general counsel and secretary at Cornerstone Therapeutics ($CRTX). Release

Senomyx ($SNMX) announced that Kent Snyder, CEO and chairman of the board of directors, will be retiring from the CEO position as of Jan. 2, 2014. He will continue to serve in his position on the board. Release

The Arthritis Foundation appointed Ann Palmer as the organization's president and CEO. The national foundation funds research aimed at restoring mobility and is active in the healthcare policy arena. Release

Tenex Health has appointed Jay Hallinan as its new CEO, and Doug Kohrs has been appointed executive chairman of Tenex's board. Previously, Hallinan worked for Stryker Neurovascular. Release | Item

Barbara Byrd Keenan, currently the executive vice president of the Institute of Food Technologists, will join the Endocrine Society as CEO. Release

Biotech IT

John Doyle, formerly a programmer and software engineer for IBM, was hired as vice president of information technology at Gentris. Release

Pharma

SciClone Pharmaceuticals ($SCLN) brought on Nancy Chang as a member of its board of directors. Release

Cubist Pharmaceuticals ($CBST) appointed Kenneth Martin to its board of directors. Martin most recently was chief financial officer and vice chairman of Wyeth and serves on the board of WABCO Holdings. Release

Devices

Illumina ($ILMN) named Dr. Richard Klausner as the company's senior vice president and chief medical officer. Dr. Klausner has previously served as a liaison to the White House Office of Science and Technology Policy and as a chief strategy adviser for USAID. Release

CRO

Theorem Clinical Research named Joseph Sgherza to head its infectious disease franchise. Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.